307 related articles for article (PubMed ID: 34125397)
21. Levodopa Improves Behavioral Deficits of Mice with Parkinson's Disease Symptoms via Curbing NLRP3 Inflammasome Activation and Enhancing Tyrosine Hydroxylase Levels in the Striatum and Substantia Nigra.
Chen X; Wang Z; Yang W; Fu Y
J Integr Neurosci; 2024 Jan; 23(1):2. PubMed ID: 38287845
[TBL] [Abstract][Full Text] [Related]
22. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
[TBL] [Abstract][Full Text] [Related]
23. Piperine improves levodopa availability in the 6-OHDA-lesioned rat model of Parkinson's disease by suppressing gut bacterial tyrosine decarboxylase.
Hu X; Yu L; Li Y; Li X; Zhao Y; Xiong L; Ai J; Chen Q; Wang X; Chen X; Ba Y; Wang Y; Wu X
CNS Neurosci Ther; 2024 Feb; 30(2):e14383. PubMed ID: 37528534
[TBL] [Abstract][Full Text] [Related]
24. Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.
Czarnecka A; Lenda T; Domin H; Konieczny J; Smiałowska M; Lorenc-Koci E
Brain Res; 2013 Dec; 1541():92-105. PubMed ID: 24129225
[TBL] [Abstract][Full Text] [Related]
25. The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Jones CK; Bubser M; Thompson AD; Dickerson JW; Turle-Lorenzo N; Amalric M; Blobaum AL; Bridges TM; Morrison RD; Jadhav S; Engers DW; Italiano K; Bode J; Daniels JS; Lindsley CW; Hopkins CR; Conn PJ; Niswender CM
J Pharmacol Exp Ther; 2012 Feb; 340(2):404-21. PubMed ID: 22088953
[TBL] [Abstract][Full Text] [Related]
26. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Harkavyi A; Abuirmeileh A; Lever R; Kingsbury AE; Biggs CS; Whitton PS
J Neuroinflammation; 2008 May; 5():19. PubMed ID: 18492290
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
[TBL] [Abstract][Full Text] [Related]
29. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
30. Reevaluation of the striatal role in the expression of turning behavior in the rat model of Parkinson's disease.
Mura A; Feldon J; Mintz M
Brain Res; 1998 Oct; 808(1):48-55. PubMed ID: 9795128
[TBL] [Abstract][Full Text] [Related]
31. Continuous dopaminergic stimulation counteracts L-DOPA-induced overactivity of Ca
Fu J; Zhao X; Tian F; Yu X
Exp Brain Res; 2022 Aug; 240(7-8):1933-1941. PubMed ID: 35699744
[TBL] [Abstract][Full Text] [Related]
32. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
33. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
King JM; Muthian G; Mackey V; Smith M; Charlton C
Life Sci; 2011 Oct; 89(17-18):638-43. PubMed ID: 21871902
[TBL] [Abstract][Full Text] [Related]
34. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
Taravini IR; Larramendy C; Gomez G; Saborido MD; Spaans F; Fresno C; González GA; Fernández E; Murer MG; Gershanik OS
Neuropharmacology; 2016 Feb; 101():576-89. PubMed ID: 25963416
[TBL] [Abstract][Full Text] [Related]
35. Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model.
Inden M; Abe M; Minamino H; Takata K; Yoshimoto K; Tooyama I; Kitamura Y
J Pharmacol Sci; 2012; 119(1):10-9. PubMed ID: 22510520
[TBL] [Abstract][Full Text] [Related]
36. MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
Jonkers N; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Nov; 407(3):281-91. PubMed ID: 11068024
[TBL] [Abstract][Full Text] [Related]
37. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of dopamine receptors in cholinergic motoneurons of the hypoglossal nucleus in a 6-OHDA-induced Parkinson's disease rat model.
Zhou L; Wang ZY; Lian H; Song HY; Zhang YM; Zhang XL; Fan RF; Zheng LF; Zhu JX
Biochem Biophys Res Commun; 2014 Sep; 452(3):560-6. PubMed ID: 25172664
[TBL] [Abstract][Full Text] [Related]
39. Hypertrophy of medial globus pallidus and substantia nigra reticulata in 6-hydroxydopamine-lesioned rats treated with L-DOPA: implication for L-DOPA-induced dyskinesia in Parkinson's disease.
Tomiyama M; Mori F; Kimura T; Ichinohe N; Wakabayashi K; Matsunaga M; Baba M
Neuropathology; 2004 Dec; 24(4):290-5. PubMed ID: 15641587
[TBL] [Abstract][Full Text] [Related]
40. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
